Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B

Wong, Vincent Wai‐Sun; Wong, Grace Lai–Hung; Tse, Chi‐Shing; Yuen, Lilly; Chan, H.L.-Y.; Locarnini, Stephen; Chan, Henry Lik‐Yuen

doi:10.1007/s10620-011-1816-6

Cited by 8 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our patient, the genomic mutation pattern of HBV revealed the presence of a single mutation (rtM204I), previously described for adefovir 12. The administration of tenofovir induced a rapid normalisation of HBV-DNA and liver enzymes levels, suggesting that this mutation does not induce the development of resistance to tenofovir.…”

Section: Discussionsupporting

confidence: 66%

Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence?

et al. 2015

View full text Add to dashboard Cite

SUMMARYWe describe a case of a 61-year-old man with chronic hepatitis B, hepatitis B e antibody (HBeAb) positive, treated with tenofovir disoproxil fumarate (TDF), who developed virological and biochemical viremic reactivation with an increase in transaminase plasma levels. The patient's history revealed that he had discontinued TDF about 5 days before admission and, from December 2013, had been taking venlafaxine, paroxetine and zolpidem for some episodes of depression. Clinical evaluation and laboratory findings excluded the presence of systemic diseases that might have been able to explain the drug inefficacy, while pharmacological evaluation suggested a possible drugdrug interaction. In order to assess the possible occurrence of resistance, mutational analysis of hepatitis B virus (HBV) was performed and excluded the presence of resistance for TDF. TDF was prescribed, and venlafaxine, paroxetine and zolpidem were discontinued. The follow-up at 3, 6 and 12 months documented a good response to TDF with a time-related decrease of HBV-DNA and alanine aminotransferase. BACKGROUND

show abstract

Section: Discussionsupporting

confidence: 66%

Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence?

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Therefore, in telbivudine-treated patients with incomplete virological response, resistance testing is recommended, particularly among those with HBV DNA>2,000 IU/ml. Knowing the presence of amino acid mutations before switching therapy will assist the proper choice of antiviral drug to avoid crossresistance in subsequent treatment [26]. Tenofovir may be a better alternative to entecavir if rtM204I and/or rtL180M were present.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Entecavir Switch Therapy in Chronic Hepatitis B Patients with Incomplete Virological Response to Telbivudine

Wong

et al. 2013

Antiviral Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, mutations associated with LAM resistance were seen in 6.3% (n=3) of 48 treatment-experienced cases. Rates of LAM resistance have been reported as 69.7% by Wen et al [24] in China, 52.9% by Wong et al [31] in Hong Kong, and 17.3% by Margeridon-Thermet et al [32] in California. Rates of HBV resistance to LAM in treatment-experienced patients in Turkey were reported as 42.6% by Sayan et al [33] , 28.8% by Timur et al [8] , 22.6% by Bozdayı et al [27] , 19.5% by Alagözlü et al [34] , 15.6% by Aydoğan et al [26] , and 7.6% by Saran et al [28] .…”

Section: Discussionmentioning

confidence: 98%

Detection of Hepatitis B Virus Drug Resistance Mutations by Pyrosequencing Method

Çimentepe¹,

Yıldırım²,

Kömür³

et al. 2019

mjima

View full text Add to dashboard Cite

Giriş: Kronik hepatit B virüs (HBV) enfeksiyonun uzun süreli tedavisi sırasında nükleoz(t)id analoglarına karşı ilaç direnci mutasyonlarının gelişmesi tedavi başarısızlığına yol açabilen önemli bir sorundur. Bu çalışmanın amacı kronik hepatit B enfeksiyonu olan hastalarda HBV ilaç direnci gen mutasyonlarının pyrosequencing metodu ile araştırılmasıdır. Gereç ve Yöntem: Kasım 2013 ve Mayıs 2014 tarihleri arasında, kronik hepatit B enfeksiyonu olan 89'u tedavi almayan (naif) ve 48'i tedavi alan toplam 137 hastaya ait serum örnekleri lamivudin (LAM), adefovir, telbivudin (TEL), entekavir (ETV) ve tenofovir (TDF) ile ilişkili ilaç direnç mutasyonlarının tespiti için real-time polimeraz zincir reaksiyonu testi sonrası pyrosequencing metodu (PyroStar HBV Drug Resistance Test, Altona Diagnostics, Germany) ile analiz edilmiştir. Bulgular: Tedavi almayan 89 hastada, TDF'ye duyarlılığı azaltan rtA194T mutasyonu bir (%1,1) olguda bulunmuştur. Tedavi edilen 48 hastada, LAM ve TEL'e ilaç direnci ve ETV'ye karşı da çapraz dirence sebep olan rtM204I mutasyonu bir (%2,1) olguda tespit edilmiştir. Kompansatuvar mutasyon olan rtL180M iki (%4,2) hastada gözlenmiştir. ETV direncini gösteren rtT184S mutasyonu ile birlikte rtM204V'nin varlığı bir (%2,1) hastada tespit edilmiştir. ÖzIntroduction: The development of drug resistance mutations to nucleos(t)ide analogues during long-term therapy for chronic hepatitis B virus (HBV) infection is a major problem that may lead to treatment failure. The aim of this study was to investigate the HBV drug resistance gene mutations in patients with chronic HBV infection by pyrosequencing method. Materials and Methods: Between December 2013 and May 2014, serum samples collected from 137 patients with chronic HBV infection, (89 treatment-naive and 48 treatment-experienced), were analyzed with real-time polymerase chain reaction analysis followed by pyrosequencing (PyroStar HBV Drug Resistance Test, Altona Diagnostics, Germany) for drug resistance mutations associated with lamivudine (LAM), adefovir, telbivudine (TEL), entecavir (ETV), and tenofovir (TDF). Results: Of the 89 treatment-naive patients, one (1.1%) had the rtA194T mutation, associated with reduced susceptibility to TDF. Of the 48 treatment-experienced patients, one (2.1%) had the rtM204I mutation, associated with drug resistance to LAM, TEL, and cross-resistance to ETV. Compensatory mutation rtL180M was observed in two patients (4.2%). The presence of rtM204V combined with rtT184S mutation indicating ETV resistance was detected in one patient (2.1%). Conclusion: The incidence of drug resistance mutations was 8.3% in treatment-experienced and 1.1% in treatment-naive patients. The use of pyrosequencing technology before and during treatment of patients with chronic HBV infection would contribute to the rapid detection of drug resistance mutations. Abstract Mehmet

show abstract

Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B

Cited by 8 publications

References 29 publications

Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence?

Reactivation of chronic hepatitis B during treatment with tenofovir disoproxil fumarate: drug interactions or low adherence?

Efficacy of Entecavir Switch Therapy in Chronic Hepatitis B Patients with Incomplete Virological Response to Telbivudine

Detection of Hepatitis B Virus Drug Resistance Mutations by Pyrosequencing Method

Contact Info

Product

Resources

About